A phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Cen, P. [1 ]
Daleiden, A. [1 ]
Doshi, G. [1 ]
Amato, R. [1 ]
机构：
[1] Univ Texas Houston, Sch Med, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16056
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC)
    Molina, A. M.
    Feldman, D. R.
    Ginsberg, M. S.
    Fischer, P.
    Trinos, M. J.
    Patil, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [2] Recombinant Interleukin-21 Plus Sorafenib for Metastatic Renal Cell Carcinoma (MRCC): A Phase I Dose Escalation Study
    Bhatia, Shailender
    Curti, Brendan D.
    Gordon, Michael S.
    Quinn, David I.
    Mendelson, David
    Dodds, Michael G.
    Hunder, Naomi N.
    Thompson, John A.
    JOURNAL OF IMMUNOTHERAPY, 2008, 31 (09) : 928 - 928
  • [3] A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC)
    Giessinger, S.
    Amato, R. J.
    Jac, J.
    Saxena, S.
    Willis, J. P.
    Chiang, S. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] A phase I study of S-1 in combination with sorafenib in metastatic renal cell carcinoma (mRCC).
    Ozono, Seiichiro
    Takayama, Tatsuya
    Fujisawa, Masato
    Miyake, Hideaki
    Hashine, Katsuyoshi
    Ninomiya, Iku
    Tatsugami, Katsunori
    Sakai, Hideki
    Ohba, Kojiro
    Akaza, Hideyuki
    Tsukamoto, Taiji
    Naito, Seiji
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [5] A Phase 1 Study of Everolimus and Sorafenib for Metastatic Clear Cell Renal Cell Carcinoma
    Harzstark, Andrea L.
    Small, Eric J.
    Weinberg, Vivian K.
    Sun, Janine
    Ryan, Charles J.
    Lin, Amy M.
    Fong, Lawrence
    Brocks, Dion R.
    Rosenberg, Jonathan E.
    CANCER, 2011, 117 (18) : 4194 - 4200
  • [6] Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Feldman, D. R.
    Kondagunta, G. V.
    Ronnen, E. A.
    Fischer, P.
    Chang, R.
    Baum, M.
    Ginsberg, M. S.
    Ishill, N.
    Patil, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Phase I of axitinib and everolimus in metastatic solid tumors and extension to metastatic renal cell carcinoma (mrcc): Results of EVAX study
    Ravaud, A.
    Gomez-roca, C.
    Picat, M. Q.
    Digue, L.
    Chevreau, C.
    Gimbert, A.
    Chauzit, E.
    Asselineau, J.
    Cornelis, F.
    Sitta, R.
    Aziza, R.
    Daste, A.
    Bikfalvi, A.
    Pedenon-perichout, D.
    Doussau, A.
    Molimard, M.
    Delord, J. P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S57 - S57
  • [8] Phase I Trial of Everolimus Plus Sorafenib for Patients with Advanced Renal Cell Cancer
    Amato, Robert J.
    Flaherty, Amber L.
    Stepankiw, Mika
    CLINICAL GENITOURINARY CANCER, 2012, 10 (01) : 26 - 31
  • [9] SAFETY PROFILE OF SUNITINIB AND SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Massari, Francesco
    Sperandi, Francesca
    Cricca, Antonia
    Melotti, Barbara
    Martoni, Andrea Angelo
    ANNALS OF ONCOLOGY, 2009, 20
  • [10] Final results of a phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer (mRCC)
    Puzanov, Igor
    Flaherty, Keith T.
    Atkins, Michael B.
    McDermott, David F.
    Wright, John J.
    Vermeulen, Wendy
    Harlacker, Kathleen
    Hsu, Arlene
    Rothenberg, Mace L.
    Sosman, Jeffrey A.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3340S - 3341S
12345